Condensed Consolidated Statements of Cash Flows (USD $) In Thousands	9 Months Ended
	Jun. 30, 2011	Jun. 30, 2010
Cash flow from operating activities:
Net Income	$ 331	$ 509
Adjustments to reconcile net income to net cash used in operating activities:
Depreciation and amortization	6,458	3,670
Change in fair value of derivative liabilities	902	1,460
Equity based compensation	328	303
Provision for doubtful accounts and sales returns and adjustments	3,059	2,759
Non-cash interest related to convertible notes payable	21	886
Deferred income taxes	1,101	(566)
Amortization of non-cash debt issuance costs	0	23
Reserve for inventory obsolescence	28	0
Loss (Gain) on disposal of assets	(2)	2
Changes in operating assets and liabilities:
Accounts receivable	(4,279)	(5,420)
Deferred advertising	(12,765)	(7,988)
Inventory	(922)	(1,135)
Other assets	(36)	(320)
Accounts payable	1,667	3,516
Accrued liabilities	60	(51)
Other liabilities	(58)	(3)
Net Cash Flow Used in Operating Activities	(4,107)	(2,355)
Cash flow from investing activities:
Purchase of property and equipment and other	(306)	(1,531)
Acquisition of SGV Medical Supplies (see Note 3)	(466)	0
Proceeds from the sale of assets	3	5
Purchase of certificates of deposit	0	(559)
Net Cash Flow Used in Investing Activities	(769)	(2,085)
Cash flow from financing activities:
Proceeds from the sale of common stock	0	7,000
Costs associated with the sale of common stock	0	(407)
Proceeds from the exercise of warrants	0	1,556
Proceeds from employee stock purchase plan	64	102
Proceeds from credit line facility	500	0
Costs associated with new credit line facility	(51)	0
Purchase of treasury stock	0	(9)
Payments of debt and capital lease obligations	(613)	(711)
Net Cash Flow Provided by (Used in) Financing Activities	(100)	7,531
Net increase (decrease) in cash	(4,976)	3,091
Cash at beginning of period	7,428	3,798
Cash at end of period	2,452	6,889
Supplemental disclosure of cash flow information:
Cash paid for interest	51	323
Cash paid for income taxes	5	20
Supplemental schedule of non-cash investing and financing activities:
Common stock issued for interest expense	0	45
Common stock issued for conversion of debt	5,100	8,914
Promissory note issued for acquisition of SGV Medical Supplies (see Note 3)	$ 107	$ 0